StockData

Alumis vs Coya Therapeutics

ALMS and COYA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALMS and COYA compare

Alumis is the larger company, worth 9.5 times as much as Coya Therapeutics ($665M against $70.4M).

Coya Therapeutics keeps more of each dollar of sales as profit, with a net margin of −643% compared with −5933% at Alumis.

Coya Therapeutics scores higher on the StockData Score (7 against 6 for Alumis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALMSCOYA
Size and price
Market cap$665M$70.4M
Share price$5.14$3.00
Change, 1 year−2.7%−49.7%
Beta (5Y)2.092.14
Employees2248
StockData Score
Total score67 (better)
Valuation score11
Growth score01 (better)
Performance score00
Health score55
Dividend score00
Valuation
P/S89.9×15.0× (better)
P/B1.5× (better)2.1×
FCF yield−52.9%–
Fair value–$2.58
Margin of safety–−16.2%
Growth
Revenue growth (TTM)–17.6%
Profitability
Operating margin−6204%−675% (better)
Net margin−5933%−643% (better)
FCF margin−4755%–
Return on equity−93.6% (better)−99.2%
Financial health
Debt / equity0.000.00
Current ratio6.747.24 (better)
Altman Z-score−0.912.76 (better)
Piotroski F-score23 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions91.3%33.1%
Held by insiders30.5%5.1%
Insider net buying, 12 months$44.7M–
Short interest, % of float12.3%6.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.